MBRX: moleculin.com Earnings per share for the last twelve months

Graphic logo of moleculin.com (MBRX)

Moleculin Biotech, Inc. (MBRX) delegates clinical trials to external CROs to maintain capital flexibility. However, the development of innovative oncology platforms remains risky due to pressure from resource behemoths. A network of Western CMOs guarantees stable drug production, and by tracking the fundamental TTM earnings per share on GURU.Markets, we note that the value -12.00 describes the company's current level of asset management efficiency.

MBRX Moleculin Earnings per share for the last twelve months (07/04/2022 - 11/15/2026)

Moleculin (MBRX) - metric breakdowns and financial figures

- share price and expert price forecast:
Stock Quotes Moleculin Biotech|MBRX - Fair Value Consensus
- market capitalization information:
Market Value Moleculin Biotech Inc|MBRX - Full Business Value
- shareholders' equity book value data:
Net Assets per Single Share Moleculin Biotech|MBRX - Company Book Value|Market Capitalization to Book Value Ratio moleculin.com|MBRX - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Moleculin Biotech, Inc.|MBRX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Moleculin Biotech, Inc.|MBRX - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Moleculin Biotech, Inc.|MBRX - Long-Term Debt|Company Short-Term Debt Moleculin Biotech|Quick Liquidity moleculin.com
- earnings and multiples data:
MBRX - Net Income|Expected Profit Moleculin Biotech, Inc.|MBRX - Business Payback Period|Future Price to Earnings Moleculin Biotech|MBRX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Moleculin Biotech, Inc.|MBRX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Moleculin Biotech|MBRX - Earnings per share for the last twelve months|Quarterly EPS earnings growth moleculin.com|MBRX - Earnings per share growth rate in current year|Earnings growth forecast for next year Moleculin Biotech, Inc.
- sales and revenue indicators:
MBRX - Company Sales|Company Future Sales Volume Moleculin Biotech, Inc.|MBRX - P/S Multiple|Price-to-Projected Revenue Ratio Moleculin|MBRX - Sales Growth YoY (Last Twelve Months)
Summary company analysis:MBRX - moleculin.com
Flagship merchandise of Moleculin Biotech Inc

Moleculin Biotech, Inc. (MBRX) represents a high-tech biotechnology sector focused on the development of the drug annamycin. Net income per share dynamics over the last four quarters reflect the actual efficiency of capital allocation. This indicator is calculated as the ratio of total annual net income to the total number of issued shares. For a company awaiting Phase 2 results for leukemias, negative values for this metric confirm the investment growth stage. A stable trend in this indicator will determine the future financial sustainability of the business.

Main competitors

GERN: Net earnings per share for the last 12 months|Earnings per share for the trailing year NBTX (Nanobiotix SA)|Bicycle Therapeutics plc (BCYC) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months CTMX (CytomX Corp)|Earnings per share for the last twelve months Perspective Therapeutics|Earnings per share for the last twelve months GNLX|Net earnings per share (EPS TTM) MOLN|Net earnings per share (EPS TTM) Oncolytics (ONCY)|Lisata Therapeutics, Inc. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters GRTX (Galera)|Molecular Templates Corp - Net earnings per share (EPS TTM)